Significance of D-dimer in Assessment of Severity and Mortality of COVID-19 Patients A Tertiary Care Hospital Study
Keywords:COVID-19, D-dimer, prognostic marker
AbstractThe outbreak of COVID-19 has brought public health emergency worldwide and has been the biggest challenge to date. This study aims to study the correlation between D-dimer levels with severity and mortality in COVID-19 patients. This study will help us understand the disease's progression and monitor the disease severity and mortality in Covid-19 patients. This retrospective descriptive study was conducted over four months from April 2021- to June 2021 in a tertiary care hospital in Central Karnataka. Demographic details and clinical and laboratory parameters were obtained from electronic hospital records. Inclusion criteria are Patients who were RT-PCR confirmed positive cases were only included in this study. Exclusion criteria are Patients who had cancer, hematologic malignancies, and acute coronary syndrome were all excluded. Results of the research are A total of 75 cases were evaluated and analyzed in this study. Patients were categorized based on severity as mild to moderate and severe. Out of which 50 patients had recovered from the illness, and 25 patients have succumbed to death. Our study revealed that elevated D-dimer levels were significant (p<0.02) with the outcome of the disease, and with the mean level of 929.27 in severe patients and 466.47 in mild-moderate patients, elevated D-dimer were highly significant (p<0.001) with the severity of the disease. Conclusion research detailed investigations of 75 COVID-19 patients suggests that a significant increase in D-dimer levels was associated with mortality and severity of the disease. Therefore, we strongly recommend that the D-dimer be used to screen patients with COVID-19 to evaluate the severity and predict the prognosis and mortality in hospitalized COVID-19 patients during admission and follow-up throughout hospitalization.
Ghaith, M. M., Albanghali, M. A., Aldairi, A. F., Iqbal, M. S., Almaimani, R. A., Alquthami, K., … Almasmoum, H. A. (2021). Potential Predictors of Poor Prognosis among Severe COVID-19 Patients: A Single-Center Study. Canadian Journal of Infectious Diseases and Medical Microbiology, 2021. https://doi.org/10.1155/2021/6656092.
Hadid T, Kafri Z, Al-Katib A. (2021). Coagulation and anticoagulation in COVID-19. Blood Rev, 47, 100761. DOI: 10.1016/j.blre.2020.100761
Halaby R, Popma CJ, Cohen A, Chi G, Zacarkim MR, Romero G, et al. (2015). D-dimer elevation and adverse outcomes. J Thromb Thrombolysis, 39(1), 55–9. DOI: 10.1007/s11239-014-1101-6
Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C. & Wang, X. (2020). Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of Translational Medicine, 18(206). DOI: 10.1186/s12967-020-02374-0
Mattiuzzi C, Lippi G. (2020). Which lessons shall we learn from the 2019 novel coronavirus outbreak? Ann Transl Med, 8, 48.
Poudel A, Poudel Y, Adhikari A, Aryal BB, Dangol D, et al. (2021) D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. Plos One, 16(8), e0256744. https://doi.org/10.1371/journal.pone.0256744
Shah S, Shah K, Patel SB, Patel FS, Osman M, Velagapudi P, Turagam MK, Lakkireddy D, Garg J. (2020). Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: A Systematic Review and Meta-Analysis. Cardiol Rev, 28(6), 295-302.
Soni M, Gopalakrishnan R, Vaishya R, Prabu P. (2020). D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. Diabetes Metab Syndr Clin Res Rev, 14, 2245–2249. pmid:33395786
Valerio L, Ferrazzi P, Sacco C, Ruf W, Kucher N, Konstantinides S V., et al. (2021). Course of D-dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients. Thromb Haemost, 121(1), 98–101.DOI: 10.1055/s-0040-1721317
Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. (2020). D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care, 8, 49. pmid:32665858
Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. (2020). D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost, 18, 1324–1329. pmid:32306492
Zheng J. (2020). SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat. Int J Biol Sci, 16(10), 1678-85. doi: 10.7150/ijbs.45053
Zhou F, Yu T, Du R, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395, 1054–1062
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395, 1054–1062.
How to Cite
Publishing your paper with Medical Laboratory Technology Journal (MLTJ) means that the author or authors retain the copyright in the paper. MLTJ granted an author(s) rights to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by MLTJ in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
MLTJ journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially. MLTJ journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.